SALVAGE INTRAVESICAL THERAPY WITH INTERFERON-α2B PLUS LOW DOSE BACILLUS CALMETTE-GUERIN IS EFFECTIVE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER IN WHOM BACILLUS CALMETTE-GUERIN ALONE PREVIOUSLY FAILED
- 1 October 2001
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 166 (4) , 1300-1305
- https://doi.org/10.1016/s0022-5347(05)65757-6
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDERJournal of Urology, 2000
- 5-YEAR FOLLOWUP OF A RANDOMIZED PROSPECTIVE STUDY COMPARING MITOMYCIN C AND BACILLUS CALMETTE-GUERIN IN PATIENTS WITH SUPERFICIAL BLADDER CARCINOMAJournal of Urology, 1999
- INTERFERON-RESISTANT TRANSITIONAL CELL CARCINOMAS (TCC) HAVE DEFECTIVE SIGNAL TRANSDUCTION FACTORSJournal of Urology, 1999
- Additional bacillus calmette-guérin therapy for recurrent transitional cell carcinoma after an initial complete responseUrology, 1997
- Bacillus calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancerUrology, 1996
- Urinary Cytokines During Intravesical Bacillus Calmetteguerin Therapy for Superficial Bladder Cancer: Processing, Stability and Prognostic ValueJournal of Urology, 1996
- Interleukin-6 Production by Bladder Tumors is Upregulated by BCG ImmunotherapyJournal of Urology, 1995
- Analysis of early failures after intravesical instillation therapy with bacille Calmette‐Guerin for carcinoma in situ of the bladderBritish Journal of Urology, 1995
- A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette–Guérin for Transitional-Cell Carcinoma of the BladderNew England Journal of Medicine, 1991
- Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response.Journal of Clinical Investigation, 1990